This work investigated the functional role of nuclear factor-kappa B (NF-κB) in respiratory burst activity and in expression of the human phagocyte NADPH oxidase genes CYBB, CYBA, NCF1, and NCF2. U937 cells with a stably transfected repressor of NF-κB (I-κBα-S32A/S36A) demonstrated significantly lower superoxide release and lower CYBB and NCF1 gene expression compared to control U937 cells. We further tested EBV-transformed B cells from patients with anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID), an inherited disorder of NF-κB function. Superoxide release and CYBB gene expression by EDA-ID cells were significantly decreased compared to normal cells and similar to X-linked chronic granulomatous disease (X91 0 CGD) patient cells. NCF1 gene expression in EDA-ID S32I cells was decreased compared to normal control cells and similar to autosomal recessive (A47 0 ) CGD cells. Gel shift assays demonstrated loss of recombinant human p50 binding to a NF-κB site 5' to the CYBB gene in U937 cells treated with NF-κB inhibitors, repressor-transfected U937 cells, and EDA-ID patients' cells. Zymosan phagocytosis was not affected by transfection of U937 cells with the NF-κB repressor. These studies show that NF-κB is necessary for CYBB and NCF1 gene expression and activation of the phagocyte NADPH oxidase in this model system. normal and anhidrotic ectodermal dysplasia leukocytes Essential role of nuclear factor-kappa B for NADPH oxidase activity in http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests Information about reproducing this article in parts or in its entirety may be found online at: http://www.bloodjournal.org/site/misc/rights.xhtml#reprints Information about ordering reprints may be found online at: http://www.bloodjournal.org/site/subscriptions/index.xhtml Information about subscriptions and ASH membership may be found online at: digital object identifier (DOIs) and date of initial publication. indexed by PubMed from initial publication. Citations to Advance online articles must include final publication). Advance online articles are citable and establish publication priority; they are appeared in the paper journal (edited, typeset versions may be posted when available prior to Advance online articles have been peer reviewed and accepted for publication but have not yet
with several cytosolic proteins, including p47 PHOX , p67 PHOX , p40 PHOX , and a GTPbinding protein, either rac1 in macrophages or rac2 in neutrophils. 2 The activated complex generates large quantities of superoxide and other reactive oxygen species essential for the microbicidal function of phagocytes.
Molecular genetic defects affecting components of the NADPH system lead to chronic granulomatous disease (CGD), a primary immunodeficiency characterized by early onset of severe recurrent infections. 1 The genes CYBB and NCF1 are the most frequent sites of mutations (~60% and 30% of the cases) leading respectively to the X-linked and one of the autosomal forms of CGD. 3;4 The CYBB gene (MIM 306400), encoding gp91 phox , is localized at chromosome Xp21.1 and contains 13 exons spanning 30 kb. 5 The CYBB promoter region includes several cis-elements involved in gene regulation by interferon-gamma (IFN-γ) and tumor necrosis factor-α (TNF-α). 6 Several trans-activators and repressors have also been characterized.
Removal of repressor elements permits interactions of both widely-expressed and IFN-γ-responsive transcriptional activators with cognate binding sites in the CYBB proximal promoter. 7;8 The NCF1 gene (MIM 608512 ) is localized at chromosome 7q11.23 and encodes p47 PHOX , a cytosolic component of the oxidase. 3 Li et al. 9 characterized the NCF1 promoter and identified a functional binding site for the transcriptional factor
For personal use only. on August 31, 2017 . by guest www.bloodjournal.org From PU. 1 . Further experiments confirmed that differentiation-dependent up-regulation of NCF1 gene transcription is associated with changes in PU.1 phosphorylation and increased binding affinity. 10 The transcription factor nuclear factor-kappa B (NF-κB) is a heterodimer formed from members of the mammalian rel gene family, which includes p105/p50, p100/p52, p65 (RelA), RelB, and c-Rel. 11;12 The general mechanism of activation of the classical and most common NF-κB complex (p50/RelA) starts with its sequestration in the cytoplasm by interaction with a family of inhibitory proteins, termed IκBs, including IκBα, IκBβ, IκBγ, IκBε, and the proto-oncogene Bcl-3.
Activation by extracellular signals induces phosphorylation of IκB by specific IκB kinases (IκKα and IκKβ) on critical serine residues, Ser32 and Ser36, within the Nterminal signal response domain. 13 IκB phosphorylation leads rapidly to its ubiquitinization and rapid proteolytic degradation, thus releasing the NF-κB heterodimer to move into the cell nucleus. There it interacts with κB-responsive promoter elements to modulate transcription of genes involved in myriad functions, including pro-inflammatory cytokines, chemokines, adhesion molecules and inducible enzymes which regulate both the innate and adaptive immune responses. 14 The inhibition of this system can be accomplished by varied pharmacological tools, such as non-steroidal anti-inflammatory drugs, anti-inflammatory steroid hormones, and toxins. 15 We have previously demonstrated that dexamethasone inhibits the NADPH oxidase system of differentiated THP-1 monocyte/macrophage cells by inhibiting CYBB and NCF1 gene expression. 16 Gauss et al. recently proposed that TNF-α-dependent activation of NF-κB upregulates the human phagocyte NADPH oxidase activity, leading to enhanced superoxide production; increased CYBB, NCF1, and NCF2 gene expression; and
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From further NF-κB activation, potentially contributing to sustained oxidant production in chronic inflammation. 17 Anrather et al. have identified two putative NF-κB binding sites in the murine gp91 PHOX gene promoter and demonstrated suppression of gp91 PHOX expression by IκBα in murine monocytic and microglial cell lines. 18 In addition, we have recently identified (C.P., A.C.-N., and P.E.N., manuscript in preparation) a putative NF-κB binding site within a DNase I hypersensitive region of the distant 5' flanking region, 19 approximately 15 kb upstream of the human CYBB transcription start site. To date, no NF-κB binding sites have been identified in the human CYBA, NCF1 or NCF2 genes.
The present work investigates the role of NF-κB on human CYBB (gp91 PHOX ), CYBA (p22 PHOX ), NCF1 (p47 PHOX ), and NCF2 (p67 PHOX ) gene expression, using pharmacological inhibitors, a human myelomonocytic cell line stably transfected with an IκB "super-inhibitor," and EBV-transformed B cells from patients with anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) due to naturally-occurring mutations in the NF-κB pathway.
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MATERIALS AND METHODS

Cells and culture conditions
The human monocytic U937 cell line derived from a diffuse histiocytic lymphoma was obtained from the American Type Culture Collection (ATCC; Rockville, MD, USA).
U937 cells transfected with an empty pCMV3 plasmid vector or a pCMV3 vector containing a FLAG-tagged construct of an IκBα with mutations of serines 32 and 36 to alanine were kindly provided by Dr. Carlos V. Paya. 20 The IkB-S32A/S36A mutant impedes phosphorylation of IκB, leading to sequestration of NF-κB in the cytoplasm. U937 cells were cultured (0.5-1x10 6 cells/mL) in RPMI 1640 complete medium supplemented with 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 100 U/mL penicillin, and 100 µg/ml streptomycin at 37°C in a humidified 5% CO 2 atmosphere. In order to induce differentiation, wild type or mutated U937 cells were cultured with IFN-γ (100 U/ml) and TNF-α (1000 U/ml) for up to 72 hrs, in the presence or absence of the NF-κB inhibitors 1 µM dexamethasone or 10 µM gliotoxin. 16;21 EBV-transformed B cells prepared from peripheral blood mononuclear cells express the phagocyte flavocytochrome b and possess NADPH oxidase activity. 22;23 Patient-derived cell lines accurately reproduce the biochemical and molecular defects of CGD. [22] [23] [24] EBV-transformed B cells were prepared according to previously published procedures 22 from normal donors, patients with X-linked or autosomal recessive CGD, and two patients with EDA-ID. The X-linked CGD patient has a CYBB mutation characterized previously as a A>G substitution at the -2 position in the splice acceptor/donor site of intron 9, leading to exon 10 deletion, lack of gp91phox expression and an impairment of the respiratory burst. 25 The autosomal recessive CGD patients have the following gene mutations: CYBA, deletion of exons For personal use only. on August 31, 2017. by guest www.bloodjournal.org From 2-5; NCF1, gt deletion (common to most A47 CGD kindreds 26 ); and NCF2, splice site mutation in exon4.
EBV-transformed B cell lines were prepared from peripheral blood of previously-described patients with EDA-ID and severe recurrent infections. One patient has X-linked EDA-ID caused by a hemizygous hypomorphic mutation in the gene encoding NEMO/IKKγ (W420X), the regulatory subunit of the IκB kinase (IKK) complex, 27 leading to impairment of NF-κB activation in this patient's cells. 28;29 The second patient has an autosomal-dominant form of EDA-ID associated with a heterozygous hypermorphic mutation (S32I) at serine 32 of I-κBα. 30 This gain-offunction mutation enhances the inhibitory capacity of I-κBα by preventing its phosphorylation and degradation, resulting in impaired NF-κB activation. 30 All reagents were endotoxin free (<10 pg/ml as tested by Limulus amebocyte lysate assay). Informed consent was obtained from all patients according to the Declaration of Helsinki.
Superoxide release
Superoxide release was assessed by a superoxide dismutase-inhibitable cytochrome c reduction assay, modified as previously described. 31 Briefly, U-937 or EBV-transformed B cells were cultured in six-well polystyrene plates (1 x 10 6 cells/well) for up to 72 hours. On the day of the experiment, the plates were centrifuged, the supernatant removed, and the cells incubated in Hanks balanced salt solution (without phenol red) containing cytochrome c (625µg/mL) for 1 h at 37°C in a humidified 5% CO 2 atmosphere. Half of the wells received superoxide dismutase (75 U/ml) at the beginning of the incubation. In another set of identical plates, phorbol myristate acetate (PMA; 30 nM) was used during the incubation period as an For personal use only. on August 31, 2017. by guest www.bloodjournal.org From activator of superoxide release. After incubation, all plates were placed on ice, and the remaining wells received superoxide dismutase. The plates were centrifuged again, and the optical absorbance of the supernatants measured at 550 nm. The amount of superoxide released was calculated using an extinction coefficient of 0.021 nM -1 cm -1 .
Real-time PCR
Total RNA was isolated from U-937 or EBV-transformed B cells ( CGA TTT CCC-3´. Cycle conditions for the ABI 5700 thermal cycler were: for gp91 PHOX : 50°C for 2 min, 95°C for 10 min and then 35 cycles of 95°C for 15 sec and 60°C for 1 min. Cycle conditions for the ABI 7500 thermal cycler were: for p22 PHOX , p47 PHOX , and p67 PHOX : 50°C for 2 min, 95°C for 10 min and then 40 cycles of 95°C for 15 sec and 60°C for 1 min. After 35 cycles, a dissociation curve (melting curve) was generated in the range of 60°C to 95°C. Parallel amplification of β actin (Gene Bank NM 001101) was used to normalize the amount of template. The reactions were run in triplicate and the results represented as mean ± SD. Standard curves for each amplification product were generated from 10-fold dilutions of pooled cDNA to determine primer efficiency.
Electromobility gel shift assays
Nuclear extracts from 10 7 U-937 or EBV-transformed B cells were prepared by a modification of the technique described by Dignam. 32 After an initial 10-minute incubation with 0.1 mM diisopropylfluorophosphate, cells were washed twice in ice 
Phagocytosis of zymosan particles
U937 cells (2 x 10 6 cells/mL) -either wild-type, transfected with SSFV empty vector, or transfected with the IkB-S32A/S36A NF-κB inhibitor -were treated or not with IFN-γ (100U/mL) for 48 hrs before incubation with Zymozan particles (2 x 10 7 particles/mL) at 37°C for 2h. Zymosan particles were opsonized or not with 10% human fresh serum for 30 minutes at 37°C before phagocytosis assays. The number of cells phagocytizing zymosan particles was determined by counting cells containing two or more zymozan particles in at least five fields (minimum of 200 cells) and was expressed as a percentage of the total number of U937 cells.
Statistics
Results are expressed as mean ± SD. Descriptive statistics were performed and comparisons among groups were established by the Mann-Whitney test. A p value <0.05 was considered significant. Phagocytosis assays were analyzed by one-way ANOVA; p value <0.05 was considered significant.
Full IRB approval for these studies was obtained at all of the participating institutions: 
RESULTS
In order to test the functional effect of NF-κB inhibition on human myelomonocytic cells, we first examined superoxide release (a measure of phagocyte NADPH oxidase activity) by the U937 cell line, in the presence of NF-κB inhibitors, and by U937 subclones transfected with an IκB S32A/S36A "super-repressor" construct or its empty vector. As shown in Figure 1 We also tested the effects of more specific suppression of NF-κB function by an IκB "super-repressor" that has been mutated to prevent phosphorylation at the critical serines. Figure 3 In order to investigate the binding activity of NF-κB to CYBB gene we performed electrophoretic mobility shift assays (EMSA) with wild type or transfected U937 cells and EBV-transformed B cell lines from a normal donor, an X-linked CGD patient, and the two EDA-ID patients. Figure 7 , panel A, shows that NF-κB, immunoprecipitated by antibody to p50, specifically bound to a radiolabeled 22 bp oligonucleotide representing the distant upstream NF-κB CYBB site. The left and middle groups of lanes show that nuclear extract from U937 and U937 pMCV3 cells, differentiated with IFN-γ and TNFα, bound significantly more probe than U937 IκB S32A/S36A cells (50-fold mean increase, n=6, p<0.05, Mann Whitney test). 
DISCUSSION
NF-κB is an essential transcription factor for multiple genes related to the immune response and development. 12;14 Our previous studies of dexamethasone, a multifunctional steroid hormone that inhibits NF-κB function among many other effects, had demonstrated inhibition of the phagocyte NADPH oxidase system at the transcriptional level (CYBB and NCF1 genes) in THP-1 myelomonocytic cells. 16 We hypothesized that NF-κB could be a key element in this inhibitory effect. The current study investigated the role of NF-κB in superoxide release and the expression of the CYBB gene, encoding the gp91 PHOX component of NADPH oxidase, in U937 myelomonocytic cells.
Our results show that the NF-κB inhibitors dexamethasone and gliotoxin diminished both superoxide release and CYBB gene expression, confirming our previous studies in a different cell line. 16 In addition, dexamethasone and gliotoxin prevented NF-κB binding to the consensus region as demonstrated by EMSA assays (NF-κB/ p50/ DNA consensus binding sequence).
Following the results using pharmacologic inhibitors on U937 cells, we further analyzed the interaction between NF-κB and the CYBB, CYBA, NCF1 and NCF2 genes, using the model of U937 cells transfected with a mutated IκB S32A/S36A gene, which can not be phosphorylated at the two target serines and hence avoids proteosome degradation. This modified gene acts as a super-inhibitor of NF-κB activity. 20 The same parameters were evaluated in cells with an empty pCMV3 vector as a negative control. These experiments showed that cells transfected with the super-inhibitor demonstrated diminished respiratory burst activity, CYBB and NCF1 gene expression, comparable to results with dexamethasone.
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From To confirm the suppression of NF-κB by IκB S32A/S36A, we performed gel shift assays using U937 cells with or without the mutated gene. In cells stimulated with IFN-γ and TNF-α and transfected with the super-inhibitor, there was no detectable binding activity of NF-κB to an oligonucleotide probe representing its consensus binding site, confirming that the transcription factor was not translocated to the nucleus. This binding activity was also inhibited by dexamethasone and gliotoxin, coincident with the inhibitory effect of these drugs on superoxide release and CYBB expression. These findings provide a functional basis for the addition of NF-κB as a new transcriptional element in the cast of proteins that take part on the regulation of CYBB gene expression.
Our findings in human myelomonocytic cells confirm and extend the previous report by Anrather et al. 18 in a murine model, in which they observed a lack of NAPDH oxidase activity in leukocytes, fibroblasts and neural cells after overexpression of IκBα or knock-out of p65/RelA. We also wished to test the relevance of the impairment of the NAPDH oxidase activity caused by natural defects in the NF-κB pathway, particularly whether NF-κB dysfunction would lead to a defect in the ability of the immune system to prevent infections.
Primary defects in the NADPH oxidase system interfere with the microbicidal activity of phagocytic cells, leading to the phenotype of CGD. On the other hand, defects in components of NF-κB activation can result in a heterogeneous group of immunodeficiencies. [34] [35] [36] [37] One form of defective NF-κB activation derives from hypomorphic mutations in genes encoding protein kinases responsible for the phosphorylation of IκB in the IκB kinase complex by the regulatory unit NEMO (NF-κB essential modulator). The resultant clinical syndrome of EDA-ID may be inherited either as an X-linked Mendelian recessive trait or by autosomal recessive or For personal use only. on August 31, 2017. by guest www.bloodjournal.org From dominant inheritance. [34] [35] [36] [37] We included in this study a case of autosomal dominant EDA-ID derived from a mutation affecting the IκBα molecule at serine 32, similar to the in vitro construct used in the present study. 30 EBV-transformed B cells mimic genetic disorders of the NADPH oxidase, 22;23 and provide a useful model system for testing its molecular defects. The current study used B cell lines from two patients with EDA-ID to examine the effects of inherited defects in NF-κB activation on the function of the NADPH oxidase. Fresh blood cells were not available from these kindreds, because the X-linked EDA-ID patient carrying the X420W NEMO mutation is deceased and the autosomal dominant EDA-ID patient carrying the S32I IkB-alpha mutation has received a hematopoietic stem cell transplant. 29 We compared superoxide release in two EDA-ID cell lines, compared to EBV-transformed B cells from a normal control and from patients with X-linked, A22, A47, and A67 CGD. One EDA-ID patient has X-linked disease caused by a hemizygous hypomorphic mutation in the gene encoding NEMO/IKKγ (W420X), the regulatory subunit of the IκB kinase (IKK) complex, 27 leading to impairment of NF-κB activation in this patient's cells. The other patient has an autosomal-dominant form of EDA-ID associated with a heterozygous hypermorphic missense mutation (S32I) at serine 32 of IκBα. 30 This gain-of-function mutation enhances the inhibitory capacity of IκBα by preventing its phosphorylation and degradation, resulting in impaired NF-κB activation.
Experiments performed with EBV-transformed B cells from the EDA-ID patients showed decreased expression of the CYBB gene and consequently impaired respiratory burst, similar to the biochemical features of cells from patients with X-linked CGD. 1;25 In addition the EDA-ID IκB S32I cell line showed diminished expression of NCF1, similar to a p47 phox -deficient CGD cell line, confirmed the findings in the IκB S32A/S36A transfected U937 cell line. These results suggest an additional mechanism for the susceptibility to infections in EDA-ID patients, 27;30 as the molecular defect in NF-κB activation also appears to affect cells of the myeloid lineage.
Pneumococcus is by far the most common infecting agent in EDA-ID, found in over 80% of patients, 27;30;38 whereas pneumococcus and other catalase-positive organisms are not associated with CGD. 38 .On the other hand, staphylococcus is both the second most common causative agent in EDA-ID patients and the most frequent pathogen in CGD patients. EDA-ID patients also show increased susceptibility to infection by mycobacteria 27, 28, 39 . X-linked EDA-ID due to a hypomorphic mutation in NEMO was first reported in a boy who died of miliary tuberculosis, 40 but EDA-ID patients present more often with less virulent mycobacteria such as Mycobacterium avium complex. 39 CGD patients are susceptible to Mycobacterium tuberculosis [41] [42] [43] [44] [45] and, in regions that utilize immunizations with bacille Calmette-Guérin (BCG), frequently present with adverse reactions to the organism. 41-43;46 The current studies suggest that common defects in NADPH oxidase activity may provide a basis for the clinical overlap between CGD and EDA-ID. The differences in phenotype probably occur because NF-κB is a ubiquitous transcription factor in the immune system, involved in the expression of genes related not only to innate immunity but also to the acquired immune system. However, as the current Furthermore, NF-κB dysfunction also affects NCF1 gene expression in this model system, providing a second possible reason for defective respiratory burst activity in EDA-ID patients.
We conclude that proper binding of NF-κB is necessary for human CYBB and NCF1 gene expression and NADPH oxidase activity. Defects in this pathway found in certain forms of ectodermal dysplasia caused by mutations affecting the NF-κB pathway may lead to a CGD-like functional defect in myeloid cells, in addition to the known myeloid and lymphoid immune defects, and may contribute to the severe immunodeficiency. Future studies examining primary phagocytes from EDA-ID patients for respiratory burst and bactericidal activity will help to correlate specific NF-κB pathway mutations with biochemical defects, as well as with agents causing infections. Cell lines were derived from: Lane 1, normal donor; Lane 2, an X-linked CGD patient; and Lanes 3 and 4: two EDA-ID patients. Superoxide generation in EDA-ID cells was significantly lower than that in the normal cell line (P<0.05, n=6, Mann-Whitney test) and equivalent to that in the X-linked CGD cell line.
Figure 5: CYBB gene expression in EBV-transformed B cell lines.
Cell lines were derived from: Lane 1, normal donor; Lane 2, an X-linked CGD patient; and Lanes 3 and 4: the designated EDA-ID patients. CYBB gene expression by EDA-ID cells was significantly lower than that in the normal cell line (P<0.05, n=6, Mann-Whitney test) and equivalent to that in the X-linked CGD cell line.
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From Figure 6 : CYBB, CYBA, NCF-1 and NCF-2 gene expression in EBV-transformed B cell lines. Cell lines were derived from: Lane 1, normal donor; Lane 2, X-linked CGD; Lane 3, A22-CGD; Lane 4, A47-CGD; Lane 5, A67-CGD; Lane 6, EDA-ID IκB S32I; Lane 7, EDA-ID NEMO/IKKγ W420X. Panel A shows that CYBB gene expression in EDA-ID cells was significantly lower than that in the normal cell line or other CGD cell lines (P<0.05, n=4, Mann-Whitney test) and equivalent to that in the X-linked CGD cell line. Panel B shows that CYBA gene expression was only affected in the A22 CGD cell line (P<0.05, n=4, Mann-Whitney test). Panel C shows that NCF-1 gene expression by EDA-ID IκB S32I was significantly lower than that in the normal cell line or other CGD cell lines (P<0.05, n=4, Mann-Whitney test) and equivalent to that in the A47 CGD cell line. Panel D shows that NCF-2 gene expression was only partially affected in the EDA-ID IκB S32I cell line (P>0.05, n=4, Mann-Whitney test) but almost abolished in the A67 CGD cell line (P<0.05, n=4, Mann-Whitney test).
Figure 7: Electrophoretic mobility shift assay of NF-κB binding activity in U937 cells and EBV-transformed B cell lines.
Panel A: In wild type (left panels) and pMCV3-transfected (middle panels) U937 cells, induction by IFN-γ and TNF-α caused an increase in binding activity of p50/Rel to an oligonucleotide representing the distant upstream NF-κB site in the CYBB gene. Binding activity was inhibited by dexamethasone (DEXA) or gliotoxin (GTX). No NF-κB binding activity was observed in U937 transfected with the super-inhibitor IκB S32A/S36A, regardless of pharmacological treatment. Representative image, n=6. Panel B: Cell lines were derived from: Lane 1, normal donor; Lane 2, a CGD patient; and Lanes 3 and 4: two EDA-ID patients. Normal B cell nuclei showed considerable binding activity of p50/Rel to an oligonucleotide representing the distant upstream NF-κB site in the CYBB gene, as also observed in the B cell line from a patient with X-linked CGD. Reduced formation of the NF-κB complex was observed in B cell lines derived from the patients with EDA-ID. Representative image, n=4.
